Medical therapy for benign prostatic hyperplasia: The road ahead

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 92-96

  Kirby, R S ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; INDORAMIN; PHENOXYBENZAMINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

CONFERENCE PAPER; FATIGUE; HUMAN; MALE; MALE SEXUAL DYSFUNCTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; VERTIGO;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG COMBINATIONS; FORECASTING; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031397591     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00808.x     Document Type: Article

References (32)

1. Berry SJ, Coffey DS, Walsh PC. Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984: 132: 474-9
2. Garraway W, Collins G. Lee R. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991: 338: 469-71
3. Lepor H. Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1994: 45: 406-13
4. Guess H, Heyse J, Gormley G. The effect of iinasteride on prostate specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7
5. Lepor H. A Department of Veterans Affairs (VA) cooperative randomised, placebo-controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosinJfinasteride combination therapy in men with clinical BPH. ; Urol 1996; 155: 587A
6. Lepor H. Does prostate volume (PV) predict response to terazosin and finasteride monotherapy and terazosinJ finasteride combination therapy? A subset analysis of the VA Cooperative BPH medical therapy study. J Urol 1996; 155: 574A
7. Boyle P. Gould A. Prostate volume predicts outcome of treatment of BPH with finasteride meta-analysis of randomised clinical trials. J Urol 1996: 155: 572A
8. Caine M. Perlnerg S. Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4
9. Brooks ME. Sidi AA, Hanani Y. Braf Z. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study. Urology 1983; 21: 474-8
10. Abrams P, Shah P, Stone A. Choa R. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-30
11. Ramsay J, Scott GI. Whitfield HN. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction. Br J Urol 1985; 57: 657-9
12. Jardin A, Bensadoun H. Delauche-Cavalier MC. Attali P. Alfusozin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-61
13. Teillac P, DeLauche-Cavalier M, Attali P, DUALF Group. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58-64
14. Hansen B, Nordling J, Mensink H, Walter S, Meyhoff H, ALFECH Study Group. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1993; 157 (Suppl.): 169-76
15. Bendix Holme J, Christensen MM, Rasmussen PC et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol 1994; 28: 77-82
16. Chappie C, Christmas T, Milroy E, Abrams P, Kirby R. A three month placebo-controlled study of doxazosin on prostatic outflow obstruction. ; Urol 1992; 147: 366A
17. Fawzy A, Braun K, Lewis GP et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-10
18. Stott MA, Abrams PH. Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol 1991; 67: 499-501
19. lacovou JW, Dunn M. Indoramin - an effective new drug in the management of bladder outflow obstruction. Br J Urol 1987; 60: 526-8
20. Chow W, Hahn D, Sandhu D et al. Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br J Urol 1990; 65: 36-8
21. Martorana G, Giberti C, Damonte P. The effect of prazosin in benign prostatic hypertrophy: A placebo-controlled double-blind study. IRCS Med Sei 1984; 12: 11-12
22. Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction, J Urol 1983; 130:275-8
23. Kirby R, Coppinger S, Corcoran M, Chappie C, Flannigan M, Milroy E. Prazosin in the treatment of prostatic obstruction. A placebo controlled study. Br J Ural 1987: 60: 136-42
24. Chappie CR, Christmas TJ. Milroy EJG. A twelve-week placebo controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 1990: 45 (Suppl. 1): 47-55
25. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology 1988: 32: 27-31
26. Lepor H, Auerbach S, Puras-Baez A et al. A randomised, placebo-controlled multicentre study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
27. Fabricius PG, Weizert P, Dunzendorfer U, MacHannaford J, Maurath C. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: A randomised placebo controlled clinical trial. Prostate 1990; 3 (Suppl.): 85-93
28. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kalo H. Use of an alpha-1 blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-12
29. Abrams P, Schulman C, Vaage S, European Tamsulosin Study Group. Tamsulosin, a selective alpha1c-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). Br J Urol 1995; 76: 325-36
30. Gormley G, Stoner E, Bruskewitz R et al. The effect of flnasteride in men with benign prostatic hyperplasia. New Eng J Med 1992; 327: 1185-91
31. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-9
32. Andersen J, Ekman P, Wolf H et al. Can flnasteride reverse the process of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-7